India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
How are some people's brains able to fight off Alzheimer's disease? Why do some people have the biological signs and damage of Alzheimer's disease , but their memory and intellectual abilities do not decline? Scientists have discovered the answer to this question. Why do some people have the biological signs and damage of Alzheimer's disease, but their memory and intellectual abilities do not decline? Scientists have discovered the answer to this question. According to researchers at the Netherlands Institute for Neuroscience , a rare and special type of immature cells in the brains of such people manage to survive and fight off the damage of the disease, so they do not show symptoms of Alzheimer's. The discovery, published in the journal Cell Stem Cell , raises hopes for the development of completely new treatments to slow the progression of dementia and preserve memory. Why does Alzheimer's disease affect people differently? This has always been a great myst...